The global pet medical device market is experiencing significant growth. According to industry research data, the market exceeded US$14 billion in 2025 and is projected to maintain a CAGR of over 8% through 2030. Key drivers include rising pet owner spending willingness, the aging pet population trend, and the increasing adoption of minimally invasive treatment technologies.
Within this growth wave, cold atmospheric plasma (CAP/DBD) technology is becoming one of the most closely watched technology directions in the pet medical device sector.
Cold Plasma Technology: A Leap from Human Medicine to Veterinary Care
Dielectric Barrier Discharge (DBD) cold plasma technology first gained widespread application in human medicine. The U.S. Food and Drug Administration (FDA) has approved multiple cold plasma-based medical devices through the De Novo classification pathway for wound treatment and tissue repair.[1]
In recent years, this technology has gradually extended into the veterinary field. Multiple clinical studies published in peer-reviewed journals have shown that DBD cold plasma has significant therapeutic effects on common pet skin inflammations, post-surgical wound infections, chronic ulcers, and other conditions.[2]
Market Growth Drivers
- Pet Humanization Trend: More pet owners regard their pets as family members and are willing to invest greater resources in their medical care
- Demand for Non-Pharmaceutical Therapies: Concerns about antibiotic resistance are driving demand for physical treatment solutions
- Veterinary Clinic Equipment Upgrades: Competition is pushing veterinary clinics to adopt more advanced medical devices to improve service quality
- Expanding Export Markets: Emerging markets in Asia-Pacific, the Middle East, and elsewhere are showing rapidly growing demand for pet medical devices
Certification & Regulatory Trends
Regulatory agencies worldwide are increasingly refining certification requirements for pet medical devices. The FDA has established clear classification and certification pathways for animal medical devices, and the EU has strengthened management of veterinary devices through the MDR regulation.[3] This creates a structural advantage for companies with international certification credentials.
DGE Pet's core technology is derived from the FDA De Novo-certified cold plasma medical system. Its manufacturing facilities comply with ISO quality management system requirements, and its products are exported to over 40 countries and regions including the United States, the European Union, and Japan.
Outlook
As technology advances and market education deepens, the application prospects for cold atmospheric plasma technology in veterinary medicine are broad. Industry forecasts indicate that over the next 3–5 years, more CAP/DBD-based pet medical products will enter the market, driving the entire industry toward safer, non-invasive, and more effective treatment approaches.